JP6254163B2 - 新規カッパオピオイドリガンド - Google Patents
新規カッパオピオイドリガンド Download PDFInfo
- Publication number
- JP6254163B2 JP6254163B2 JP2015527656A JP2015527656A JP6254163B2 JP 6254163 B2 JP6254163 B2 JP 6254163B2 JP 2015527656 A JP2015527656 A JP 2015527656A JP 2015527656 A JP2015527656 A JP 2015527656A JP 6254163 B2 JP6254163 B2 JP 6254163B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- cycloalkyl
- groups
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(N)N=C(c1cc2cc(C)ccc2nc1N1CC(CO)*CC1)O Chemical compound CC(N)N=C(c1cc2cc(C)ccc2nc1N1CC(CO)*CC1)O 0.000 description 7
- WJOWOMIYYZYBQI-UHFFFAOYSA-N C(CC1)CCC1N=C(CC1)CCN1c1nc2ccccc2cc1-c1ncc[o]1 Chemical compound C(CC1)CCC1N=C(CC1)CCN1c1nc2ccccc2cc1-c1ncc[o]1 WJOWOMIYYZYBQI-UHFFFAOYSA-N 0.000 description 1
- XUVXHJLKZJBIPA-UHFFFAOYSA-N CC(/N=C(/c(c(N(CC1)CCC1NC1CCOCC1)nc1c2)cc1ccc2F)\O)=N Chemical compound CC(/N=C(/c(c(N(CC1)CCC1NC1CCOCC1)nc1c2)cc1ccc2F)\O)=N XUVXHJLKZJBIPA-UHFFFAOYSA-N 0.000 description 1
- ZDEAZLGLOLYMEG-UHFFFAOYSA-N CC(C)CNC(CC1)CCN1c1nc2cc(F)ccc2cc1C1ONC(C)N1 Chemical compound CC(C)CNC(CC1)CCN1c1nc2cc(F)ccc2cc1C1ONC(C)N1 ZDEAZLGLOLYMEG-UHFFFAOYSA-N 0.000 description 1
- BOBIUQMIKFMMAY-UHFFFAOYSA-O CC(N)/N=C(/c1c(N(CC2)CC2NC2CCCCC2)nc(cccc2)c2c1)\[OH2+] Chemical compound CC(N)/N=C(/c1c(N(CC2)CC2NC2CCCCC2)nc(cccc2)c2c1)\[OH2+] BOBIUQMIKFMMAY-UHFFFAOYSA-O 0.000 description 1
- FJYNJNALPQYAOC-UHFFFAOYSA-N CCC(C(CNc(nc(CCC1)c1c1)c1C1=NC(C)NO1)CO)NC1CCCCC1 Chemical compound CCC(C(CNc(nc(CCC1)c1c1)c1C1=NC(C)NO1)CO)NC1CCCCC1 FJYNJNALPQYAOC-UHFFFAOYSA-N 0.000 description 1
- GYXGDPSOHIBSSD-UHFFFAOYSA-N CCC(CCNc1nc2ccc(C)cc2cc1/C(/O)=N/C(C)N)NC1CCCCC1 Chemical compound CCC(CCNc1nc2ccc(C)cc2cc1/C(/O)=N/C(C)N)NC1CCCCC1 GYXGDPSOHIBSSD-UHFFFAOYSA-N 0.000 description 1
- CPPROKVMDBRLSE-OVQYCZRQSA-N CCC[C@@H](CN(CC1)c(c(/C(/N=O)=N/[IH]C)cc2c3)nc2ccc3F)[C@@H]1NCC(C)C Chemical compound CCC[C@@H](CN(CC1)c(c(/C(/N=O)=N/[IH]C)cc2c3)nc2ccc3F)[C@@H]1NCC(C)C CPPROKVMDBRLSE-OVQYCZRQSA-N 0.000 description 1
- SVXNQCSEWWFWGP-UHFFFAOYSA-N Cc1cc(C=N)c(N(CCC2NC3CCCCC3)CC2OC)nc1 Chemical compound Cc1cc(C=N)c(N(CCC2NC3CCCCC3)CC2OC)nc1 SVXNQCSEWWFWGP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683861P | 2012-08-16 | 2012-08-16 | |
| US61/683,861 | 2012-08-16 | ||
| PCT/US2013/055313 WO2014028829A1 (en) | 2012-08-16 | 2013-08-16 | Novel kappa opioid ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017228495A Division JP2018058873A (ja) | 2012-08-16 | 2017-11-29 | 新規カッパオピオイドリガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531764A JP2015531764A (ja) | 2015-11-05 |
| JP2015531764A5 JP2015531764A5 (enExample) | 2016-07-28 |
| JP6254163B2 true JP6254163B2 (ja) | 2017-12-27 |
Family
ID=50101521
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527656A Active JP6254163B2 (ja) | 2012-08-16 | 2013-08-16 | 新規カッパオピオイドリガンド |
| JP2017228495A Pending JP2018058873A (ja) | 2012-08-16 | 2017-11-29 | 新規カッパオピオイドリガンド |
| JP2020010476A Pending JP2020090518A (ja) | 2012-08-16 | 2020-01-27 | 新規カッパオピオイドリガンド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017228495A Pending JP2018058873A (ja) | 2012-08-16 | 2017-11-29 | 新規カッパオピオイドリガンド |
| JP2020010476A Pending JP2020090518A (ja) | 2012-08-16 | 2020-01-27 | 新規カッパオピオイドリガンド |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9682966B2 (enExample) |
| EP (2) | EP2884978B1 (enExample) |
| JP (3) | JP6254163B2 (enExample) |
| AU (3) | AU2013302497A1 (enExample) |
| CA (1) | CA2882132C (enExample) |
| DK (1) | DK2884978T3 (enExample) |
| ES (1) | ES2750640T3 (enExample) |
| WO (1) | WO2014028829A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2750640T3 (es) | 2012-08-16 | 2020-03-26 | Scripps Research Inst | Ligandos opioides kappa novedosos |
| US10982041B2 (en) * | 2016-02-25 | 2021-04-20 | Swancor Advanced Materials Co., Ltd. | Epoxy resin oligomer |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| WO2018170492A1 (en) * | 2017-03-17 | 2018-09-20 | The Scripps Research Institute | Kappa opioid receptor antagonists and products and methods related thereto |
| US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019113419A1 (en) * | 2017-12-08 | 2019-06-13 | The Rockefeller University | Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| IL322808A (en) * | 2023-02-17 | 2025-10-01 | Scripps Research Inst | Quinoline derivatives used as kappa-opioid receptor agonists |
| WO2024216061A1 (en) | 2023-04-13 | 2024-10-17 | Neumora Therapeutics, Inc. | Methods of treating depression and anhedonia |
| WO2024216046A1 (en) | 2023-04-13 | 2024-10-17 | Neumora Therapeutics, Inc. | Methods of treating anhedonia |
| WO2025042657A1 (en) * | 2023-08-18 | 2025-02-27 | The Scripps Research Institute | Kappa-opioid receptor antagonists |
| WO2025051204A1 (zh) * | 2023-09-05 | 2025-03-13 | 海思科医药集团股份有限公司 | 一种kor拮抗剂及其在医药上的应用 |
| WO2025250535A1 (en) | 2024-05-28 | 2025-12-04 | Neumora Therapeutics, Inc. | Methods of treating depression and anhedonia |
| WO2025257758A1 (en) | 2024-06-11 | 2025-12-18 | Assia Chemical Industries Ltd. | Solid state forms of navacaprant |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4014171A1 (de) * | 1990-05-03 | 1991-11-07 | Basf Ag | Cyanochinolinverbindungen |
| ES2121988T3 (es) * | 1992-01-23 | 1998-12-16 | Toray Industries | Derivado de morfinano y uso medicinal. |
| WO1999042461A1 (en) | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
| DE59914996D1 (en) * | 1998-04-20 | 2009-05-14 | Abbott Gmbh & Co Kg | Heterocyclisch substituierte amide als calpainhemmer |
| US6284769B1 (en) * | 1999-12-03 | 2001-09-04 | The Board Of Trustees Of The University Of Illinois | Nonpeptide kappa opioid receptor antagonists |
| US7381721B2 (en) * | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| WO2005028480A2 (en) * | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| WO2005028438A1 (ja) * | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
| ATE533745T1 (de) * | 2004-03-17 | 2011-12-15 | Pfizer Prod Inc | Neue benzyl(iden)-lactam-derivate |
| DK1812440T3 (da) * | 2004-11-04 | 2011-01-31 | Vertex Pharma | Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser |
| GB0510204D0 (en) * | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EP2388258A1 (de) | 2005-10-19 | 2011-11-23 | Grünenthal GmbH | Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| EP1940406A4 (en) * | 2005-10-21 | 2009-11-18 | Merck & Co Inc | POTASSIUM CHANNEL INHIBITORS |
| JP2010509392A (ja) * | 2006-11-13 | 2010-03-25 | ファイザー・プロダクツ・インク | ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用 |
| JP2011506462A (ja) * | 2007-12-10 | 2011-03-03 | グラクソ グループ リミテッド | メラニン凝集ホルモン受容体１アンタゴニストとしてのビス−ピリジルピリドン |
| WO2011025799A1 (en) * | 2009-08-26 | 2011-03-03 | Glaxo Group Limited | Cathepsin c inhibitors |
| CA2778484C (en) * | 2009-10-23 | 2018-07-31 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators |
| MX2012006909A (es) * | 2009-12-29 | 2012-07-10 | Suven Life Sciences Ltd | LIGANDOS DEL RECEPTOR NICOTINICO NEURONAL A4ß2 DE ACETILCOLINA. |
| TW201139406A (en) * | 2010-01-14 | 2011-11-16 | Glaxo Group Ltd | Voltage-gated sodium channel blockers |
| US8486968B2 (en) * | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
| WO2012123449A1 (en) * | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| ES2750640T3 (es) | 2012-08-16 | 2020-03-26 | Scripps Research Inst | Ligandos opioides kappa novedosos |
-
2013
- 2013-08-16 ES ES13829428T patent/ES2750640T3/es active Active
- 2013-08-16 DK DK13829428.5T patent/DK2884978T3/da active
- 2013-08-16 CA CA2882132A patent/CA2882132C/en active Active
- 2013-08-16 EP EP13829428.5A patent/EP2884978B1/en active Active
- 2013-08-16 EP EP19186416.4A patent/EP3584246A1/en not_active Withdrawn
- 2013-08-16 AU AU2013302497A patent/AU2013302497A1/en not_active Abandoned
- 2013-08-16 US US14/421,932 patent/US9682966B2/en active Active
- 2013-08-16 WO PCT/US2013/055313 patent/WO2014028829A1/en not_active Ceased
- 2013-08-16 JP JP2015527656A patent/JP6254163B2/ja active Active
-
2017
- 2017-05-15 US US15/595,436 patent/US10118915B2/en active Active
- 2017-11-29 JP JP2017228495A patent/JP2018058873A/ja active Pending
-
2018
- 2018-03-02 AU AU2018201522A patent/AU2018201522A1/en not_active Abandoned
-
2019
- 2019-10-11 AU AU2019246921A patent/AU2019246921B2/en active Active
-
2020
- 2020-01-27 JP JP2020010476A patent/JP2020090518A/ja active Pending
-
2024
- 2024-04-04 US US18/627,081 patent/US20250066336A1/en active Pending
-
2025
- 2025-07-18 US US19/274,318 patent/US20250346584A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10118915B2 (en) | 2018-11-06 |
| ES2750640T3 (es) | 2020-03-26 |
| US9682966B2 (en) | 2017-06-20 |
| DK2884978T3 (da) | 2019-09-30 |
| EP2884978B1 (en) | 2019-07-17 |
| CA2882132C (en) | 2021-07-06 |
| AU2018201522A1 (en) | 2018-03-22 |
| JP2020090518A (ja) | 2020-06-11 |
| AU2019246921B2 (en) | 2021-04-01 |
| EP2884978A1 (en) | 2015-06-24 |
| US20250066336A1 (en) | 2025-02-27 |
| AU2019246921A1 (en) | 2019-10-31 |
| EP3584246A1 (en) | 2019-12-25 |
| WO2014028829A1 (en) | 2014-02-20 |
| US20250346584A1 (en) | 2025-11-13 |
| US20150210673A1 (en) | 2015-07-30 |
| EP2884978A4 (en) | 2016-01-13 |
| US20180099954A1 (en) | 2018-04-12 |
| AU2013302497A1 (en) | 2015-03-05 |
| CA2882132A1 (en) | 2014-02-20 |
| JP2015531764A (ja) | 2015-11-05 |
| JP2018058873A (ja) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6254163B2 (ja) | 新規カッパオピオイドリガンド | |
| US9586928B2 (en) | Modulators of the nuclear hormone receptor ROR | |
| ES2672732T3 (es) | Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina | |
| WO2012009258A2 (en) | Peptidomimetic galanin receptor modulators | |
| EP2234487A1 (en) | Anilides and analogs as rho kinase inhibitors | |
| US20170327512A1 (en) | Modulators of vasopressin receptors with therapeutic potential | |
| EA021672B1 (ru) | Модуляторы рецепторов сфингозин-1-фосфата и их применение | |
| US20110038835A1 (en) | Anilides and analogs as rho kinase inhibitors | |
| US9656994B2 (en) | Substituted benzimidazoles as nociceptin receptor modulators | |
| JPWO2008139879A1 (ja) | Ｇ蛋白質共役型レセプター抑制剤および医薬 | |
| WO2012170561A1 (en) | N-benzylindole modulators of pparg | |
| BRPI0912545A2 (pt) | Novos moduladores de receptores de esfingosina fosfato | |
| US9504675B2 (en) | Alpha-ketoheterocycles and methods of making and using | |
| WO2013078237A1 (en) | N-arylylmethylindazole modulators of pparg | |
| CN115232126A (zh) | 一种β-卡波林-1,2,3-三唑化合物及其制备方法与抗阿尔兹海默病的应用 | |
| WO2014116684A1 (en) | Non-peptidic neuropeptide y receptor modulators | |
| JP6118892B2 (ja) | デュオカルマイシン類縁体の環式プロドラッグ | |
| CN104744451A (zh) | 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途 | |
| CN115974723A (zh) | 甲酰胺乙撑蒽类化合物、包含其的药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160606 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170327 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170323 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170626 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170927 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171101 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171129 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6254163 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |